Home orphan
 

Keywords :   


Tag: orphan

MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma

2014-10-01 14:02:11| drugdiscoveryonline Home Page

MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma

Tags: drug cancer treat receives

 

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

2014-09-29 15:24:53| Biotech - Topix.net

CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme , small cell lung cancer and ovarian cancer . Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin.

Tags: multiple drug grants fda

 
 

Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies

2014-09-03 12:18:47| drugdiscoveryonline Home Page

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, recently announced that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency

Tags: treatment drug receives deficiencies

 

Regulus Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome

2014-07-30 10:28:24| drugdiscoveryonline Home Page

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"), as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy

Tags: of treatment drug receives

 

Nuvilex CEO And COO Discuss Preclinical And Clinical Trials, Orphan...

2014-06-05 09:53:20| Logistics - Topix.net

Nuvilex, Inc. President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's pancreatic cancer treatment in an interview with Stock Market Media Group, a research and content development investment relations firm, while the two were attending the American Society of Clinical Oncology ... (more)

Tags: discuss clinical ceo trials

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] next »